JP2018505183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505183A5 JP2018505183A5 JP2017540652A JP2017540652A JP2018505183A5 JP 2018505183 A5 JP2018505183 A5 JP 2018505183A5 JP 2017540652 A JP2017540652 A JP 2017540652A JP 2017540652 A JP2017540652 A JP 2017540652A JP 2018505183 A5 JP2018505183 A5 JP 2018505183A5
- Authority
- JP
- Japan
- Prior art keywords
- ebola virus
- pharmaceutical composition
- viral load
- composition according
- determined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000003612 virological effect Effects 0.000 claims 5
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241001115376 Sudan ebolavirus Species 0.000 claims 2
- 241001115374 Tai Forest ebolavirus Species 0.000 claims 2
- 241001115400 Zaire ebolavirus Species 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 1
- 229950008454 favipiravir Drugs 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2015/000334 | 2015-01-28 | ||
| IB2015000334 | 2015-01-28 | ||
| IBPCT/IB2015/000351 | 2015-02-19 | ||
| IB2015000351 | 2015-02-19 | ||
| PCT/EP2016/051645 WO2016120301A1 (en) | 2015-01-28 | 2016-01-27 | Methods and pharmaceutical compositions for the treatment of ebola virus disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505183A JP2018505183A (ja) | 2018-02-22 |
| JP2018505183A5 true JP2018505183A5 (enExample) | 2018-12-20 |
Family
ID=55272459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540652A Pending JP2018505183A (ja) | 2015-01-28 | 2016-01-27 | エボラウイルス疾患の処置のための方法及び医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10098879B2 (enExample) |
| EP (1) | EP3250206A1 (enExample) |
| JP (1) | JP2018505183A (enExample) |
| WO (1) | WO2016120301A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230158020A1 (en) * | 2020-05-23 | 2023-05-25 | Alexandre Vasilievich Ivaschenko | Method for treating RNA viral infections, including COVID-19 (SARS-CoV-2) |
| EP4265252A4 (en) * | 2020-12-18 | 2024-11-27 | FUJIFILM Toyama Chemical Co., Ltd. | Pharmaceutical composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227475B1 (en) | 1998-08-20 | 2011-07-28 | Toyama Chemical Co Ltd | Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing them |
| CA2755274C (en) | 2009-03-13 | 2017-02-28 | Sahoe Kakuda | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
-
2016
- 2016-01-27 EP EP16702068.4A patent/EP3250206A1/en not_active Withdrawn
- 2016-01-27 JP JP2017540652A patent/JP2018505183A/ja active Pending
- 2016-01-27 WO PCT/EP2016/051645 patent/WO2016120301A1/en not_active Ceased
- 2016-01-27 US US15/546,362 patent/US10098879B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Balasuriya et al. | Equine arteritis virus | |
| JP2016513640A5 (enExample) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| WO2015061294A8 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
| JP2011126917A5 (enExample) | ||
| JP2015534562A5 (enExample) | ||
| JP2012194087A5 (enExample) | ||
| JP2017531673A5 (enExample) | ||
| JP2010520200A5 (enExample) | ||
| JP2017532343A5 (enExample) | ||
| JP2017511377A5 (enExample) | ||
| JP2012199532A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| BR112015000685A2 (pt) | método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza. | |
| JP2017502045A5 (enExample) | ||
| Feitelson et al. | Hepatitis B x (HBx) as a component of a functional cure for chronic hepatitis B | |
| JP2016516985A5 (enExample) | ||
| CA2863106A1 (en) | Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients | |
| JP2021511326A5 (enExample) | ||
| JP2016513723A5 (enExample) | ||
| JP2023520770A5 (enExample) | ||
| JP2015127319A5 (enExample) | ||
| Meunier et al. | Infection with a mouse-adapted strain of the 2009 pandemic virus causes a highly severe disease associated with an impaired T cell response | |
| Beltrame et al. | MASP2 gene polymorphisms and serum levels in HIV infected patients from Southern Brazil | |
| Mok et al. | Severe liver failure due to influenza A infection in a hemodialysis patient |